PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
23.06 USD
0 (0%)
Overall PCRX gets a fundamental rating of 5 out of 10. We evaluated PCRX against 196 industry peers in the Pharmaceuticals industry. PCRX has an average financial health and profitability rating. PCRX has a bad growth rate and is valued cheaply. These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PCRX has a better Return On Assets (-8.29%) than 68.88% of its industry peers.
Looking at the Return On Equity, with a value of -16.82%, PCRX is in the better half of the industry, outperforming 70.41% of the companies in the same industry.
PCRX has a better Return On Invested Capital (3.88%) than 81.12% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.17%. This is significantly below the industry average of 15.30%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
The Operating Margin of PCRX (9.90%) is better than 82.65% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX has a better Gross Margin (78.19%) than 83.67% of its industry peers.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.56, we must say that PCRX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.56, PCRX is doing good in the industry, outperforming 61.22% of the companies in the same industry.
PCRX has a debt to FCF ratio of 4.96. This is a neutral value as PCRX would need 4.96 years to pay back of all of its debts.
PCRX has a better Debt to FCF ratio (4.96) than 83.67% of its industry peers.
PCRX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.50, PCRX perfoms like the industry average, outperforming 40.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.56 |
ROIC/WACC0.54
WACC7.25%
2.3 Liquidity
A Current Ratio of 2.38 indicates that PCRX has no problem at all paying its short term obligations.
The Current ratio of PCRX (2.38) is comparable to the rest of the industry.
PCRX has a Quick Ratio of 1.91. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.91, PCRX perfoms like the industry average, outperforming 43.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.92%.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.68%.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.92% yearly.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.56% on average per year.
EPS Next Y-9.5%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.54, which indicates a rather cheap valuation of PCRX.
Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (27.70), we can say PCRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 6.93, the valuation of PCRX can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.35% of the companies listed in the same industry.
PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.15, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.54 | ||
| Fwd PE | 6.93 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 94.90% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.85 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.54
EPS Next 2Y1.81%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PCRX (10/10/2025, 1:42:00 PM)
23.06
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change0.59%
Market Cap1.04B
Analysts76.92
Price Target38.15 (65.44%)
Short Float %15.15%
Short Ratio9.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)0%
PT rev (3m)-3.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.27%
EPS NY rev (1m)0.49%
EPS NY rev (3m)3.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.54 | ||
| Fwd PE | 6.93 | ||
| P/S | 1.47 | ||
| P/FCF | 8.85 | ||
| P/OCF | 7.7 | ||
| P/B | 1.37 | ||
| P/tB | 3.29 | ||
| EV/EBITDA | 6.41 |
EPS(TTM)3.06
EY13.27%
EPS(NY)3.33
Fwd EY14.43%
FCF(TTM)2.61
FCFY11.3%
OCF(TTM)2.99
OCFY12.98%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.56 |
F-Score5
WACC7.25%
ROIC/WACC0.54
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-9.5%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%